[go: up one dir, main page]

DE69529831D1 - Änderung der aktivität und/oder spiegel von häm-oxygenase zur beherrschung von entzündung - Google Patents

Änderung der aktivität und/oder spiegel von häm-oxygenase zur beherrschung von entzündung

Info

Publication number
DE69529831D1
DE69529831D1 DE69529831T DE69529831T DE69529831D1 DE 69529831 D1 DE69529831 D1 DE 69529831D1 DE 69529831 T DE69529831 T DE 69529831T DE 69529831 T DE69529831 T DE 69529831T DE 69529831 D1 DE69529831 D1 DE 69529831D1
Authority
DE
Germany
Prior art keywords
control
inflammation
mirror
change
oxygenase activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69529831T
Other languages
English (en)
Other versions
DE69529831T2 (de
Inventor
Dean Willis
Richard Moore
Albert Willoughby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Negma Lerads SA
Original Assignee
Harvey William Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4154382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69529831(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Harvey William Research Ltd filed Critical Harvey William Research Ltd
Application granted granted Critical
Publication of DE69529831D1 publication Critical patent/DE69529831D1/de
Publication of DE69529831T2 publication Critical patent/DE69529831T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Mirrors, Picture Frames, Photograph Stands, And Related Fastening Devices (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Rear-View Mirror Devices That Are Mounted On The Exterior Of The Vehicle (AREA)
  • Medicinal Preparation (AREA)
DE69529831T 1994-09-22 1995-09-22 Änderung der aktivität und/oder spiegel von häm-oxygenase zur beherrschung von entzündung Revoked DE69529831T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002132690A CA2132690A1 (en) 1994-09-22 1994-09-22 Control and modulation of inflammatory response in humans in need of such control and modulation
PCT/GB1995/002249 WO1996009038A2 (en) 1994-09-22 1995-09-22 Alteration of activity and/or levels of haem-oxygenase to control inflammation

Publications (2)

Publication Number Publication Date
DE69529831D1 true DE69529831D1 (de) 2003-04-10
DE69529831T2 DE69529831T2 (de) 2003-12-24

Family

ID=4154382

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69529831T Revoked DE69529831T2 (de) 1994-09-22 1995-09-22 Änderung der aktivität und/oder spiegel von häm-oxygenase zur beherrschung von entzündung

Country Status (12)

Country Link
EP (1) EP0782441B1 (de)
JP (1) JPH10506388A (de)
CN (1) CN1213742C (de)
AT (1) ATE233551T1 (de)
AU (1) AU3528195A (de)
CA (1) CA2132690A1 (de)
DE (1) DE69529831T2 (de)
DK (1) DK0782441T3 (de)
ES (1) ES2192205T3 (de)
NZ (1) NZ292963A (de)
PT (1) PT782441E (de)
WO (1) WO1996009038A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127356A (en) 1993-10-15 2000-10-03 Duke University Oxidant scavengers
US5756492A (en) * 1996-09-09 1998-05-26 Sangstat Medical Corporation Graft survival prolongation with porphyrins
CA2309154C (en) 1997-11-03 2010-02-16 Duke University Substituted porphyrins
ES2257858T3 (es) 1998-04-24 2006-08-01 Duke University Porfirinas sustituidas.
AU2366900A (en) 1998-12-17 2000-07-03 Sangstat Medical Corporation Methods for enhancing graft survival by modulating heme oxygenase activity
IL144503A0 (en) 1999-01-25 2002-05-23 Nat Jewish Med & Res Center Substituted porphyrins
WO2002098431A1 (en) 2001-06-01 2002-12-12 National Jewish Medical And Research Center Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
CA2475209A1 (en) 2002-02-04 2003-08-14 Alfama - Investigacao E Desenvolvimento De Produtos Farmaceuticos Lda. Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
AU2003226366A1 (en) * 2002-04-15 2003-11-03 Beth Israel Deaconess Medical Center Use of heme oxygenase-1 and products of heme degradation
US7485721B2 (en) 2002-06-07 2009-02-03 Duke University Substituted porphyrins
FR2842738B1 (fr) * 2002-07-23 2006-02-10 Negma Lerads Utilisation d'une rheine pour la preparation d'un medicament pour le traitement de l'inflammation chronique, la prevention et le traitement du rejet des transplantations d'organes et de tissus
EP1940425A4 (de) * 2005-09-30 2010-02-03 Ovation Pharmaceuticals Inc Verfahren zur behandlung von pankreatitis
KR20160036108A (ko) 2008-05-23 2016-04-01 내셔날 쥬이쉬 헬스 알킬화 종으로의 노출과 관련된 상해를 치료하는 방법
CA2789950C (en) * 2010-02-18 2018-09-04 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
US9163044B2 (en) 2011-04-19 2015-10-20 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
WO2013013179A1 (en) 2011-07-21 2013-01-24 Alfama, Inc. Ruthenium carbon monoxide releasing molecules and uses thereof
CN105727379A (zh) * 2016-02-25 2016-07-06 顾宇春 血红素加氧酶药物洗脱支架
CN110585215B (zh) * 2019-09-19 2023-06-02 中山大学 氯化血红素及其复合物在医药中的新应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5010073A (en) * 1989-10-05 1991-04-23 The Rockefeller University Use of liposomes as carriers for metalloporphyrins
US5102670A (en) * 1990-09-14 1992-04-07 Abraham Nader G Method for treating eye disorders by reducing 12(r)-hydroxyeicosatetraenoic acid and 12(r)-dihydroxyeicosatrienoic acid levels
EP0581856B1 (de) * 1991-04-19 1999-07-14 The Children's Medical Center Corporation Verfahren zur vorbeugung nmda-rezeptorkomplex-vermittelter neuronaler schäden
DE69223157T2 (de) * 1991-09-24 1998-06-10 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Bethesda, Md. Sauerstoff-substituierte derivate von nucleophil-stickstoffoxid-addukten und ihre verwendung als stickstoffoxid-donor-prodrugs
GB9127376D0 (en) * 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
GB9200114D0 (en) * 1992-01-04 1992-02-26 Scras Dual inhibitors of no synthase and cyclooxygenase
WO1994013252A1 (en) * 1992-12-10 1994-06-23 Hemogen, Inc. Method for stimulating production of heme oxygenase using vitamin b12

Also Published As

Publication number Publication date
DE69529831T2 (de) 2003-12-24
CA2132690A1 (en) 1996-03-23
EP0782441A1 (de) 1997-07-09
WO1996009038A3 (en) 1996-06-13
WO1996009038A2 (en) 1996-03-28
ATE233551T1 (de) 2003-03-15
DK0782441T3 (da) 2003-06-30
NZ292963A (en) 2001-06-29
EP0782441B1 (de) 2003-03-05
CN1166785A (zh) 1997-12-03
PT782441E (pt) 2003-07-31
AU3528195A (en) 1996-04-09
CN1213742C (zh) 2005-08-10
ES2192205T3 (es) 2003-10-01
JPH10506388A (ja) 1998-06-23

Similar Documents

Publication Publication Date Title
DE69529831D1 (de) Änderung der aktivität und/oder spiegel von häm-oxygenase zur beherrschung von entzündung
ATE135231T1 (de) Verwendung von ''cartilage-inducing factor'' (cif) zur behandlung von hemato- oder lymphopoietischen krankheiten
DE3584172D1 (de) 17-beta-substituierte-4-aza-5-alpha-androstenone und ihre anwendung als 5-alpha-reduktase-inhibitoren.
DE69432019D1 (de) Amidin-derivate mit stickstoffoxid-synthease-aktivität
DE68908366D1 (de) Kunststoffverkapselte einheit von mutter und unterlegscheibe.
ATE128704T1 (de) Substituierte azetidinone als entzündungshemmende und antidegenerative wirkstoffe.
DE69428782D1 (de) Anstiegszeitsteuerung und Optimierung des Leistungsverbrauchs in einer Leistungsstufe
DK0719145T3 (da) Nitrogenoxiddonorpræparat til behandling af anale lidelser
DE69300548D1 (de) Verbesserungen an und hinsichtlich des Aufbringens von Beschichtungen.
FI944549A7 (fi) Allergisten ja tulehdussairauksien hoidossa käyttökelpoiset yhdisteet
ATE198895T1 (de) Verwendung von bindungsreagenzien gegen cd23 in der behandlung von autoimmunkrankheiten
ES2063060T3 (es) Benzamida contra enfermedades cognoscitivas.
DE3584974D1 (de) Zusammensetzungen von ungesaettigten polyestern oder polyesteramiden mit polycycloalkenylendgruppen und vinylaktive plastifiziermittel dazu.
ATE471985T1 (de) Protease from lucilia sericata und deren verwendung zur wundheilung
ATE209891T1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung der seborrhoischen dermatitis
EP0330218A3 (de) Lysyl-Oxidase-Inhibitoren
EE9700350A (et) COMT-inhibiitorite uus kasutamine ja diabeetiliste vaskulaarsete häirete ärahoidmise meetod
EP0635010A1 (de) Neue kardioprotektive wirkstoffe.
ATE141617T1 (de) Kontinuierliche hydrolyse von zelluloseacetat
ES2161293T3 (es) Derivados de enol acilados como profarmacos de inhibidores de la elastasa.
KR890701732A (ko) 개량형 조직 플라스미노겐 활성화 인자
ATE216884T1 (de) Verwendung von sulbutiamin zur behandlung von psychomotorischen oder psychointellektuellen beschwerden
Rusinski et al. Saving New York's soils.
NO930712L (no) Ensilasje-additiv
MY102063A (en) New use of 1,4-dihydropyridine derivatives and combinations thereof with calcitonins

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: NEGMA-LERADS, TOUSSUS-LE-NOBLE, FR

8363 Opposition against the patent
8331 Complete revocation